• MaaT033 is a Microbiome Ecosystem Therapy for oral administration, with high bacterial richness and diversity, standardized, ready to use and obtained from healthy donors
• The full results of the study are expected in the first half of 2022 and will prepare the launch of a Phase 2/3 clinical trial planned for the second half of 2022
• Four patient cohorts completed the CIMON Phase 1b study evaluating the dose of MaaT033 in patients with acute myeloid leukemia
• Proof of colonization: good colonization of the microbiota, which is maintained over time, was observed with MaaT033, associated with a satisfactory safety profile